Diversify Advisory Services LLC Purchases 91,640 Shares of Johnson & Johnson $JNJ

Key Points

• Diversify Advisory Services increased its Johnson & Johnson stake by 2,961.9% in the second quarter, purchasing 91,640 shares and bringing its holdings to 94,734 shares valued at approximately $25.2 million. Institutional investors collectively own 69.55% of J&J.
• Analysts maintain a favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $268.22; several firms recently raised their targets to between $282 and $290.
• J&J reported quarterly earnings and revenue above expectations, with revenue up 6.6% year over year, and announced a quarterly dividend of $1.34, equivalent to a 2.0% annualized yield.

Diversify Advisory Services LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2,961.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 94,734 shares of the company's stock after purchasing an additional 91,640 shares during the quarter. Diversify Advisory Services LLC's holdings in Johnson & Johnson were worth $25,195,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of JNJ. Auto Owners Insurance Co increased its holdings in shares of Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares in the last quarter. Norges Bank bought a new position in Johnson & Johnson in the fourth quarter valued at approximately $6,924,523,000. Capital World Investors acquired a new position in Johnson & Johnson in the 4th quarter worth $2,005,942,000. Diamant Asset Management Inc. boosted its position in shares of Johnson & Johnson by 24,436.5% during the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company's stock worth $109,338,000 after buying an additional 4,454,778 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in Johnson & Johnson by 41.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,423,886 shares of the company's stock worth $2,571,124,000 after acquiring an additional 3,655,754 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

JNJ has been the subject of several analyst reports. Guggenheim raised their price objective on Johnson & Johnson from $270.00 to $287.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Weiss Ratings upgraded shares of Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, July 24th. Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $272.00 to $282.00 and gave the stock an "overweight" rating in a research note on Monday, August 3rd. The Goldman Sachs Group reaffirmed a "buy" rating and set a $282.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, HSBC set a $290.00 price target on shares of Johnson & Johnson and gave the company a "buy" rating in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus target price of $268.22.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $268.30 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The stock's fifty day moving average price is $258.88 and its two-hundred day moving average price is $243.98. Johnson & Johnson has a one year low of $173.33 and a one year high of $276.47. The firm has a market cap of $646.58 billion, a price-to-earnings ratio of 31.09, a P/E/G ratio of 2.56 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company's revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson's payout ratio is 62.11%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: China approved J&J’s oral psoriasis pill, Icotyde, expanding the company’s immunology portfolio and giving it a simpler treatment option to compete with rival products from Bristol Myers Squibb and AbbVie. The pill could also broaden J&J’s presence in China, although it may compete with the company’s established injectable Tremfya franchise. China approves J&J's oral psoriasis pill
• Positive Sentiment: The FDA expanded approval of Imaavy for warm autoimmune hemolytic anemia in patients 12 and older who are receiving or have previously received steroids. As the first approved treatment for this rare, potentially life-threatening disorder, Imaavy addresses an unmet need and could support J&J’s rare-disease growth strategy. Imaavy expands into rare blood disorder
• Positive Sentiment: Recent analysis points to a favorable shift in J&J’s product mix, with newer products increasingly offsetting pressure from the STELARA patent loss. This supports the view that growth in the broader Innovative Medicine portfolio may be more important than the shrinking contribution from STELARA. Did a product swap fuel JNJ stock's surge?
• Positive Sentiment: Investors continue to view JNJ as a defensive dividend holding, supported by its balance sheet, diversified healthcare operations and ability to generate dependable returns through economic cycles. Johnson & Johnson is a top dividend stock

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the business's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares of the company's stock, valued at $4,367,458. The trade was a 48.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 63,972 shares of company stock worth $16,245,605. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source